title: [Pharmacological and clinical profiles of Dornase alfa (Pulmozyme®) in the management of cystic fibrosis patients to improve pulmonary function].
authors.affiliation: kokubohrm@chugai-pharm.co.jp
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Kokubo
authors.forename: Shunji
authors.initials: S
authors.lastname: Hosatani
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ichikawa
mesh_terms: D000280:Administration, Inhalation; D001249:Asthma / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology*; D003850:Deoxyribonuclease I / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D003851:Deoxyribonucleases / Q000378:metabolism; D016724:Empyema, Pleural / Q000188:drug therapy; D006801:Humans; D008168:Lung / Q000503:physiopathology*; D001261:Pulmonary Atelectasis / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012129:Respiratory Function Tests; D013183:Sputum / Q000187:drug effects / Q000201:enzymology; D014783:Viscosity / Q000187:drug effects
chemical_list: D011994:Recombinant Proteins; D003851:Deoxyribonucleases; D003850:Deoxyribonuclease I; C568813:dornase alfa